{"id":"gsk2340273a","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TYK2 is a non-receptor tyrosine kinase that plays a critical role in type I and type III interferon signaling and IL-23 signaling pathways. By selectively inhibiting TYK2, GSK2340273A reduces the activation and proliferation of pathogenic T cells and other immune cells involved in autoimmune and inflammatory diseases. This selective approach aims to provide efficacy while potentially minimizing some of the broader immunosuppressive effects associated with pan-JAK inhibition.","oneSentence":"GSK2340273A is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses JAK-STAT signaling in immune cells to reduce inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:39.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT01051661","phase":"PHASE3","title":"Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-12","conditions":"Influenza","enrollment":6154},{"nctId":"NCT01059617","phase":"PHASE1","title":"Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-09","conditions":"Influenza","enrollment":133},{"nctId":"NCT01035749","phase":"PHASE2","title":"Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-01","conditions":"Influenza","enrollment":310},{"nctId":"NCT00985673","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-01","conditions":"Influenza","enrollment":611},{"nctId":"NCT00979602","phase":"PHASE3","title":"Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-11-09","conditions":"Influenza","enrollment":4048},{"nctId":"NCT00985088","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-11","conditions":"Influenza","enrollment":1343},{"nctId":"NCT00976820","phase":"PHASE2","title":"Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-20","conditions":"Influenza","enrollment":323},{"nctId":"NCT01236040","phase":"PHASE1","title":"Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-11-29","conditions":"Influenza","enrollment":521}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GSK2340273A","genericName":"GSK2340273A","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"GSK2340273A is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses JAK-STAT signaling in immune cells to reduce inflammatory responses. Used for Psoriasis, Psoriatic arthritis, Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}